RareFinance peopleInnovationCareers PipelineCollaborationAdvance treatment SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Annual and

Sustainability

Reports 2023

Addressing unmet need in rare diseases

We are dedicated to developing and commercializing innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.

Chairman's letter

"As we look ahead to many exciting new milestones, the Board is confident the strong and highly experienced team at Hansa will continue to deliver on its important drug development and commercial priorities."

Peter Nicklin
Chairman, Hansa Biopharma

CEO statement

Søren Tulstrup, President and CEO

"We are poised to deliver on our bold ambition of providing life-altering and life-saving medicines to people with rare immunological diseases and conditions."

Søren Tulstrup
President and CEO, Hansa Biopharma

Strategic priorities

Hansa’s mission is to become a global leader in rare diseases through the development of innovative, lifesaving and life altering treatments for patients with rare immunological conditions.

Commercialize IDEFIRIX® in first indication and markets

Successfully launch Hansa's first authorized product IDEFIRIX in Europe.

Secure FDA approval and launch  in the U.S.

Geographical Expansion.

Advance ongoing imlifidase clinical programs

Achieve approval/usage of imlifidase in follow-on indications

Broaden the label beyond kidney transplantation.

Expand IgG-cleaving enzyme technology

Expand IgG-cleaving enzyme technology platform into gene therapy.

Develop next generation IgG-cleaving enzymes for repeat usage

Build a focused, integrated, agile and empowered international organization and seek partnerships to accelerate growth and reduce risk

Highlights 2023

Market Access

Market Access secured in the five largest European markets and in a total of 14 European markets.

Australia is the first country to grant provisional approval in kidney transplantation from both living and deceased donors.

New commercialization agreement for Middle East and North Africa.

Partnerships

Sarepta enters clinical stage with site activated in first clinical trial with imlifidase as a pre-treatment to SRP-9001 gene therapy in DMD.

New collaboration with Généthon to evaluate imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome.

Clinical advancement

Long term data of imlifidase in kidney transplantation confirms sustained benefit through to year 5 (17-HMedIdeS-14).

Encouraging high-level results for first-in-human trial with HNSA-5487 (NICE-01).

Completion of phase 2 trial in Guillain- Barré Syndrome (GBS) and positive safety, tolerability, and early efficacy outcomes in announced (15-HMedIdeS-09).

First patient dosed in the phase 3 trial of imlifidase in anti- GBM disease (GOODIDES-02).

First patient treated in investigator-initiated phase 2 trial in ANCA- associated vasculitis (ImlifidARDSe.01).

Financial position

Financed into 2025.

Market cap of approximately 132m USD (Dec. 2023).

Guideline directed consensus in desensitization treatment

Country-specific medical guidelines created in five countries across Europe following the publication in 2022 by ESOT of the first set of clinical guidelines on a management pathway for highly sensitized patients.

A Great Place to Work since 2020

Awarded Great Place to Work for the fourth consecutive year by the independent institute Great Place to Work® and selected among the best workplaces in Sweden in 2023.

Potential indication universe

Hansa's first-in-class immunoglobulin G (IgG) antibody cleaving enzyme technology has significant potential in several therapeutic indication where IgG become harmful or interfere with and undermine the success of a therapy.

The potential of IgG Modulation in autoimmune indications

Autoimmune diseases are caused by the immune system mistakenly mounting an immune attack against the body’s own cells and tissues. Hansa’s technology platform may have relevance in several autoimmune diseases where IgGs play an important role in the pathogenesis, and its action is being investigated in clinical settings in the treatment of rare autoimmune conditions.

Bridging the access to gene therapies for more patients

Sometimes, a perfectly functional immune system can have detrimental effects for a patient in need of treatment, like in the case of AAV-based gene therapies. We see the potential for our enzymes to help overcome the immunological barrier created by pre-existing neutralizing antibodies (NAbs), thereby enabling effective transfer of a healthy gene sequence into these patients.

Advancing the science of incompatible kidney transplantation

There remains an urgent need to ensure highly kidney transplant sensitized patients have access to high quality care and guideline directed desensitization strategies to enable them to receive a life-changing kidney transplant. As innovations in desensitization become more readily available Hansa continues to advance the science around desensitization.

Ushering in innovative solutions in IgG-cleaving technology

Hansa is expanding its IgG cleaving platform beyond its lead molecule, imlifidase, with HNSA-5487. Part of the NiceR program (Novel Immunoglobulin Cleaving Enzymes for Repeat dosing), HNSA-5487 is the first next-generation IgG-cleaving enzyme designed to treat conditions where there is a need to prolong the IgG-low window through re-dosing.

Sustainability Report

2023

Becoming a more sustainable business

"The continued success of Hansa hinges on more than the results we achieve. It is also about how we deliver them."

Søren Tulstrup
President and CEO, Hansa Biopharma

Our Sustainability strategy 

Hansa is committed to addressing unmet need by advancing innovative science and ensuring access to lifesaving and life-altering medicines. Our strategy ensures we are addressing the most relevant topics to our business and meet the expectations of external and internal stakeholders.

At Hansa, we have identified where we can positively contribute to the United Nations’ Sustainable Development Goals.  

UN's Sustainable Development Goals - no poverty
UN's Sustainable Development Goals - good health and well-being
UN's Sustainable Development Goals - gender equality
UN's Sustainable Development Goals - decent work and economic growth
UN's Sustainable Development Goals - peace, justice and strong institutions
UN's Sustainable Development Goals - partnerships for the goals

Addressing unmet medical needs

Ensuring equitable access to care is work we cannot do alone and requires a multi-stakeholder approach. Throughout 2023, Hansa engaged with key patient advocacy across the US and Europe to understand the needs of patients in kidney transplantation, rare disease, and autoimmune disease.

Cultivating an engaged culture by fostering inclusivity, collaboration, and innovation

As a growing biotech company with employees around the globe, we are focused on ensuring we cultivate an inclusive and diverse culture, enable employees to develop and grow, and offer a healthy and safe work environment.

Making a difference by operating an ethical, transparent, and responsible business

Hansa is committed to operating with the highest integrity and ethical standards complying with laws and regulations and driving personal accountability for employees, partners, and vendors.

Embracing sustainable decision-making and environmental stewardship

As we grow as a company, we should strive to keep our environmental impact small. This means utilizing approaches that create a default sustainable business from discovery to clinical trial design, to product launches and manufacturing. 

Addressing unmet medical needs

Ensuring equitable access to care is work we cannot do alone and requires a multi-stakeholder approach. Throughout 2023, Hansa engaged with key patient advocacy across the US and Europe to understand the needs of patients in kidney transplantation, rare disease, and autoimmune disease.

Cultivating an engaged culture by fostering inclusivity, collaboration, and innovation

As a growing biotech company with employees around the globe, we are focused on ensuring we cultivate an inclusive and diverse culture, enable employees to develop and grow, and offer a healthy and safe work environment.

Making a difference by operating an ethical, transparent, and responsible business

Hansa is committed to operating with the highest integrity and ethical standards complying with laws and regulations and driving personal accountability for employees, partners, and vendors.

Embracing sustainable decision-making and environmental stewardship

As we grow as a company, we should strive to keep our environmental impact small. This means utilizing approaches that create a default sustainable business from discovery to clinical trial design, to product launches and manufacturing. 

2023 sustainability performance highlights

32

Different nationalities

100%

Renewable electricity used

52%

Women in senior position

100%

Completion rate Great Place To Work Survey